<DOC>
	<DOC>NCT01458717</DOC>
	<brief_summary>Previous reports suggest benefit of neoadjuvant chemoradiation treatment for borderline resectable pancreas cancer. This study is a multicenter prospective randomized phase II/III study of neoadjuvant chemoradiation with gemcitabine in patients with borderline resectable pancreas cancer. The study is designed in 2 arms, one with upfront surgery and the other with neoadjuvant chemoradiation therapy.</brief_summary>
	<brief_title>Neoadjuvant Chemoradiation in Patients With Borderline Resectable Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>&gt;18 years old or &lt;75 years old ECOG 02 biopsy proven adenocarcinoma of the pancreas no history of previous chemotherapy borderline resectable pancreas cancer no distant metastasis WBC at least 3,000/mm3 or absolute neutrophil count at least 1,500/mm3, Platelet count at least 125,000/mm3 Bilirubin less than 2.5 mg/dL AST less than 5 times upper limit of normal Creatinine no greater than 1.5 times upper limit of normal informed consent history of previous chemotherapy history of radiation at &gt;25% area of bone marrow stage unspecified, with distant metastasis, recurrent pancreas cancer history of malignant neoplasm (except stage 0 cancer, skin in situ cancer except malignant melanoma). Patients who are NED after 5 years after treatment of malignant neoplasm can be candidate of this study pregnant, breastfeeding patient uncontrolled or active infection uncontrolled cardiopulmonary disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>pancreas</keyword>
	<keyword>cancer</keyword>
	<keyword>borderline resectable</keyword>
	<keyword>locally advanced</keyword>
	<keyword>resectability</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>radiation</keyword>
	<keyword>chemoradiation</keyword>
	<keyword>neoadjuvant</keyword>
	<keyword>survival</keyword>
	<keyword>prognosis</keyword>
	<keyword>recurrence</keyword>
	<keyword>response rate</keyword>
</DOC>